GE Healthcare's Life Sciences business and BeiGene, Ltd have announced that BeiGene has selected GE's FlexFactory~(TM) biomanufacturing platform for its first current Good Manufacturing Practices (cGMP) biomanufacturing facility in Suzhou, China. Currently under construction, the facility is expected to be operational by 2017. BeiGene is a clinical-stage biopharmaceutical company focused on discovering and developing innovative, molecularly-targeted and immuno-oncological drugs that address severe unmet medical needs in a variety of cancer indications. Announced in August 2015, the company's new pilot-scale facility will manufacture monoclonal antibodies in its biologics pipeline for clinical trial use.
展开▼
